Revolution Medicines price target lowered to $28 from $32 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Revolution Medicines to $28 from $32 and keeps a Buy rating on the shares post the Q3 report. The firm says Revolution’s “war chest” should thus provide an operational runway well beyond 2025 and possibly through multiple key data catalysts.